Qatar Investment Authority (QIA)

Tracked participation in 7 Atlas companies, with 0 explicitly attributed leads.

Firm website ↗

7portfolio companies

9round participations

0lead positions

Jul 2026latest activity

Capital activity

Portfolio

CompanyLatest valuationFirst → latestRoundsRoleAttributed partner

SSambaNova$11BJul 2026 → Jul 20261 roundParticipant—

RReplit$9BMar 2026 → Mar 20261 roundParticipant—

AAnthropic$380BSep 2025 → Feb 20262 roundsParticipant—

AApptronikPhysical AIApptronik is an Austin, Texas–based humanoid robotics company building “Apollo,” a general-purpose humanoid robot…$5.5Bvaluation$1.3BraisedRecent roundsSeries A-X (extension of Series A; company-reported total Series A > $935M) · Feb 2026$520M · AT&T Ventures, B Capital +5Series A (additional close; oversubscribed) · Mar 2025$403M · ARK Invest, B Capital +9Series A · Feb 2025$350M · led by B Capital, Capital FactoryApptronik$5.5BFeb 2026 → Feb 20261 roundParticipant—

PPositron$1BFeb 2026 → Feb 20261 roundParticipant—

Dd-Matrix$2BNov 2025 → Nov 20251 roundParticipant—

ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic Therapeutics—Jun 2023 → Jun 20242 roundsParticipant—

DateCompanyRoundRaisedValuationRoleEvidence

Jul 08, 2026SSambaNovaSeries F (first close)$1B$11BParticipant

Source ↗

Mar 11, 2026RReplitSeries D$400M$9BParticipant

Source ↗+1 ↗

Feb 12, 2026AAnthropicSeries G$30B$380BParticipant

Source ↗

Feb 11, 2026AApptronikPhysical AIApptronik is an Austin, Texas–based humanoid robotics company building “Apollo,” a general-purpose humanoid robot…$5.5Bvaluation$1.3BraisedRecent roundsSeries A-X (extension of Series A; company-reported total Series A > $935M) · Feb 2026$520M · AT&T Ventures, B Capital +5Series A (additional close; oversubscribed) · Mar 2025$403M · ARK Invest, B Capital +9Series A · Feb 2025$350M · led by B Capital, Capital FactoryApptronikSeries A-X (extension of Series A; company-reported total Series A > $935M)$520M$5.5BParticipant

Source ↗

Feb 04, 2026PPositronSeries B$230M$1BParticipant

Source ↗

Nov 12, 2025Dd-MatrixSeries C$275M$2BParticipant

Source ↗

Sep 02, 2025AAnthropicSeries F$13B$183BParticipant

Source ↗

Jun 18, 2024ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B extension (oversubscribed)$50M—Participant

Source ↗

Jun 18, 2023ITIambic TherapeuticsScienceIambic Therapeutics (formerly Entos) is a clinical-stage life science and technology company developing…$8.4Mvaluation$476MraisedRecent roundsOversubscribed financing round (company described as >$100M) · Nov 2025$100M · Abingworth, Alexandria Venture Investments +15Series B extension (oversubscribed) · Jun 2024$50M · led by Exor Ventures, Mubadala CapitalSeries B (oversubscribed) · Oct 2023$100M · led by Abingworth, Ascenta CapitalIambic TherapeuticsSeries B Extension$50M—Participant

Source ↗

DateCompanyRoundRaisedValuationRoleEvidence

Feb 12, 2026AAnthropicSeries G$30B$380BParticipant

Source ↗

Sep 02, 2025AAnthropicSeries F$13B$183BParticipant

Source ↗

Jul 08, 2026SSambaNovaSeries F (first close)$1B$11BParticipant

Source ↗

Mar 11, 2026RReplitSeries D$400M$9BParticipant

Source ↗+1 ↗

Nov 12, 2025Dd-MatrixSeries C$275M$2BParticipant

Source ↗

Feb 04, 2026PPositronSeries B$230M$1BParticipant

Source ↗